NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Well in my infinite wisdom I asked Bard. "He" seems to be "bamming" with me.

What is positive about getting a drug on the Recommended INN list, before it is approved, as DCVax-L now has succeeded with, and with the name Murcidencel?

There are several positive things about getting a drug on the Recommended INN list, before it is approved:

It provides a unique and nonproprietary name for the drug, which can help to improve communication and understanding of the drug in the global medical community.

It encourages national naming authorities to adopt the same name for the drug, which can help to avoid confusion and ensure that the drug is marketed consistently around the world.

It can help to raise awareness of the drug and its potential benefits to patients.

It can help to make the drug more attractive to investors and other stakeholders.

In the case of Murcidencel, a dendritic cell vaccine for glioblastoma, getting on the Recommended INN list before approval is especially positive because it can help to streamline the approval process and get the drug to patients more quickly.

Here are some specific examples of how getting a drug on the Recommended INN list can be beneficial:

It can make it easier for researchers to find and compare data on the drug from different clinical trials.

It can make it easier for patients to find information about the drug and its potential benefits and risks.

It can make it easier for doctors to prescribe the drug and for pharmacists to dispense it.
It can help to reduce the cost of the drug by making it easier for manufacturers to produce and market it.

Overall, getting a drug on the Recommended INN list is a positive development for all stakeholders involved in the development and commercialization of the drug, including patients, researchers, doctors, pharmacists, and manufacturers.